The DOI matches its Crossref record; 229 of the 229 references it cites were found in a registry or an index.
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Open accessAbstract
Current success of immunotherapy in cancer has drawn attention to the subsets of T H cells in the tumor which are critical for activation of anti-tumor response either directly by themselves or by stimulating cytotoxic T cell activity. However, presence of immunosuppressive pro-tumorigenic T H subsets in the tumor milieu further contributes to the complexity of regulation of T H cell-mediated immune response. In this review, we present an overview of the multifaceted positive and negative effects of T H cells, with an emphasis on regulation of different T H cell subtypes by various immune cells, and how a delicate balance of contradictory signals can influence overall success of cancer immunotherapy. We focus on the regulatory network that encompasses dendritic cell-induced activation of CD4+T H 1 cells and subsequent priming of CD8+cytotoxic T cells, along with intersecting anti-inflammatory and pro-tumorigenic T H 2 cell activity. We further discuss how other tumor infiltrating immune cells such as immunostimulatory T H 9 and T fh cells, immunosuppressive T reg cells, and the duality of T H 17 function contribute to tip the balance of anti- vs pro-tumorigenic T H responses in the tumor. We highlight the developing knowledge of CD4+T H 1 immune response against neoantigens/oncodrivers, impact of current immunotherapy strategies on CD4+T H 1 immunity, and how opposing action of T H cell subtypes can be explored further to amplify immunotherapy success in patients. Understanding the nuances of CD4+T H cells regulation and the molecular framework undergirding the balancing act between anti- vs pro-tumorigenic T H subtypes is critical for rational designing of immunotherapies that can bypass therapeutic escape to maximize the potential of immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · cited 1×
“Treg cells has the ability to limit the function of antigen presenting cells by CTLA-4 dependent downregulation of CD80 and CD86 expressions, thereby evading tumor antigen presentation and tumor-specific T cell activation (53).”
BackgroundRegulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
T follicular helper cell differentiation, function, and roles in disease
Crotty, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.004 · Cited by 1,847
Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828
CD4 T cells: fates, functions, and faults
Zhu, J., & Paul, W. E. (2008) · Blood · doi:10.1182/blood-2008-05-078154 · Cited by 1,798
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · cited 1×
“CD40-CD40L interaction stimulates CD80 and CD86 costimulatory molecule expression on DC and its subsequent binding with the CD28 costimulatory receptor on CD8 T cells can deliver the CD4 T cell help required for CTL activity, as observed in recent pre-clinical and clinical studies including anti-PD-1 and other immune…”
BackgroundCytotoxic CD8+ T cells in cancer and cancer immunotherapy
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
T follicular helper cell biology: a decade of discovery and diseases
Crotty, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.011 · Cited by 1,591
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
CD4 + T Cells: Differentiation and Functions
Luckheeram, R. V., Zhou, R., Verma, A. D., & Xia, B. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/925135 · Cited by 1,381
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Human dendritic cell subsets: an update
Collin, M., & Bigley, V. (2018) · Immunology · doi:10.1111/imm.12888 · Cited by 1,301 · cited 12×
“This is in line with observations demonstrating that cDC2 are better equipped for CD4+ T cell differentiation due to preferential expression of MHC-II (64, 72, 73).”
BackgroundResultInfluentialPandiyan, P., Zheng, L., Ishihara, S., Reed, J., & Lenardo, M. J. (2007) · Nature Immunology · doi:10.1038/ni1536 · Cited by 1,286
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Mechanisms of disseminated cancer cell dormancy: an awakening field
Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3793 · Cited by 1,126
Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease.
Kidd, P. M. (2003) · PubMed · Cited by 1,102
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Chaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J.-M., Jack, R. S., Wunderlich, F. T., Brüning, J. C., Müller, W., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.018 · Cited by 980
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · cited 1×
“In MMTV-PyMT spontaneous mammary carcinoma model, a unique TH1 CD4 + subset was identified in non-tumor peripheral tissues that rendered protective benefit when transferred into treatment-naïve tumor hosts challenged with 4T1 tumors (83).”
BackgroundDendritic Cells and Cancer Immunity
Gardner, A., & Ruffell, B. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.006 · Cited by 907
Human memory T cells: generation, compartmentalization and homeostasis
Farber, D. L., Yudanin, N. A., & Restifo, N. P. (2014) · Nature Reviews Immunology · doi:10.1038/nri3567 · Cited by 897 · cited 1×
“Detailed mechanisms of differentiation and function of each TM cell subtype is not discussed in this review, since it has been extensively reviewed elsewhere (5, 6).”
BackgroundSimilarities and differences in CD4+ and CD8+ effector and memory T cell generation
Seder, R. A., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni969 · Cited by 892
An essential role for the IL-2 receptor in Treg cell function
Chinen, T., Kannan, A. K., Levine, A. G., Fan, X., Klein, U., Zheng, Y., Gasteiger, G., Feng, Y., Fontenot, J. D., & Rudensky, A. Y. (2016) · Nature Immunology · doi:10.1038/ni.3540 · Cited by 888
Castellino, F., Huang, A. Y., Altan-Bonnet, G., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 855
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846
Dendritic cell subsets in T cell programming: location dictates function
Eisenbarth, S. C. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0088-1 · Cited by 827
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo
Chen, M.-L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., & Khazaie, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408197102 · Cited by 806
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Neoantigen vaccine: an emerging tumor immunotherapy
Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C., Wu, X., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 700
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S., Stover, E., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 684
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Type 2 cytokines: mechanisms and therapeutic strategies
Wynn, T. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3831 · Cited by 678
The multifaceted role of CD4+ T cells in CD8+ T cell memory
Laidlaw, B. J., Craft, J. E., & Kaech, S. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.10 · Cited by 657
Zander, R., Schauder, D., Xin, G., Nguyen, C., Wu, X., Zajac, A., & Cui, W. (2019) · Immunity · doi:10.1016/j.immuni.2019.10.009 · Cited by 648
Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 637
TH2 cell development and function
Walker, J. A., & McKenzie, A. N. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.118 · Cited by 632
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 620
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-2611-3 · Cited by 611
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602
Schlitzer, A., Sivakamasundari, V, Chen, J., Sumatoh, H. R. B., Schreuder, J., Lum, J., Malleret, B., Zhang, S., Larbi, A., Zolezzi, F., et al. (2015) · Nature Immunology · doi:10.1038/ni.3200 · Cited by 574
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553
In Vivo CD4 + T Cell Differentiation and Function: Revisiting the Th1/Th2 Paradigm
Ruterbusch, M., Pruner, K. B., Shehata, L., & Pepper, M. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-103019-085803 · Cited by 550 · cited 1×
“TH1/TH2 balance in normal and cancer-associated immune response has been reviewed in general extensively elsewhere (29, 133).”
BackgroundRole of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 549
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
Eyles, J., Puaux, A.-L., Wang, X., Toh, B., Prakash, C., Hong, M., Tan, T. G., Zheng, L., Ong, L. C., Jin, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42002 · Cited by 506
Saravia, J., Chapman, N. M., & Chi, H. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0220-6 · Cited by 489 · cited 4×
“TH2 Immune Response Polarization to the TH2 effector lineage is dependent on production of IL-4, stimulating STAT6 signaling to upregulate the GATA3 transcription factor (18, 20).”
BackgroundInfluentialThe paradoxical role of IL-10 in immunity and cancer
Mannino, M. H., Zhu, Z., Xiao, H., Bai, Q., Wakefield, M. R., & Fang, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.009 · Cited by 473
Th17 cells are long lived and retain a stem cell-like molecular signature
Muranski, P., Borman, Z. A., Kerkar, S. P., Klebanoff, C. A., Ji, Y., Sanchez-Perez, L., Sukumar, M., Reger, R. N., Yu, Z., Kern, S. J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.019 · Cited by 443
Bos, R., & Sherman, L. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1322 · Cited by 443
Dissecting the mechanisms of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0275-8 · Cited by 434
Groom, J. R., Richmond, J., Murooka, T. T., Sorensen, E. W., Sung, J. H., Bankert, K., von Andrian, U. H., Moon, J. J., Mempel, T. R., & Luster, A. D. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.016 · Cited by 433
CD4 CTL, a cytotoxic subset of CD4(+) T cells, their differentiation and function
Takeuchi, A., & Saito, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00194 · Cited by 431
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
Ahrends, T., Spanjaard, A., Pilzecker, B., Bąbała, N., Bovens, A., Xiao, Y., Jacobs, H., & Borst, J. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.009 · Cited by 413
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Vilgelm, A. E., & Richmond, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00333 · Cited by 379
Dendritic cell-mediated T cell polarization
de Jong, E. C., Smits, H. H., & Kapsenberg, M. L. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0167-1 · Cited by 367
Dendritic Cell–Based Cancer Vaccines
Santos, P. M., & Butterfield, L. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701024 · Cited by 361
T Helper Cell Differentiation, Heterogeneity, and Plasticity
Zhu, J. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a030338 · Cited by 351
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 348
Th17 Cells in Cancer: The Ultimate Identity Crisis
Bailey, S. R., Nelson, M. H., Himes, R. A., Li, Z., Mehrotra, S., & Paulos, C. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00276 · Cited by 334
The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
Mojic, M., Takeda, K., & Hayakawa, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010089 · Cited by 334
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Oft, M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0214 · Cited by 322 · cited 1×
“While IL-4, IL-5 and IL-13 have been documented to contribute to cancer growth and metastasis (21, 30, 31), a dual pro- and anti-tumorigenic role of IL-10 has been reported in recent literature, as reviewed elsewhere (32, 33).”
BackgroundRay, J. P., Staron, M. M., Shyer, J. A., Ho, P.-C., Marshall, H. D., Gray, S. M., Laidlaw, B. J., Araki, K., Ahmed, R., Kaech, S. M., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.017 · Cited by 315
The TNF Paradox in Cancer Progression and Immunotherapy
Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., & Ségui, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01818 · Cited by 305
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Byrne, A., Savas, P., Sant, S., Li, R., Virassamy, B., Luen, S. J., Beavis, P. A., Mackay, L. K., Neeson, P. J., & Loi, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0333-y · Cited by 301
Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.002 · Cited by 299
The IL-2 cytokine family in cancer immunotherapy
Sim, G. C., & Radvanyi, L. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.018 · Cited by 278
Th17 Cell Plasticity and Functions in Cancer Immunity
Guéry, L., & Hugues, S. (2015) · BioMed Research International · doi:10.1155/2015/314620 · Cited by 261
Chodon, T., Comin-Anduix, B., Chmielowski, B., Koya, R. C., Wu, Z., Auerbach, M., Ng, C., Avramis, E., Seja, E., Villanueva, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3017 · Cited by 259
Unleashing endogenous TNF-alpha as a cancer immunotherapeutic
Josephs, S. F., Ichim, T. E., Prince, S. M., Kesari, S., Marincola, F. M., Escobedo, A. R., & Jafri, A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1611-7 · Cited by 257
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Kagamu, H., Kitano, S., Yamaguchi, O., Yoshimura, K., Horimoto, K., Kitazawa, M., Fukui, K., Shiono, A., Mouri, A., Nishihara, F., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0574 · Cited by 256
Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
Clarke, J., Panwar, B., Madrigal, A., Singh, D., Gujar, R., Wood, O., Chee, S. J., Eschweiler, S., King, E. V., Awad, A. S., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190249 · Cited by 256
Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
Tai, X., Van Laethem, F., Pobezinsky, L., Guinter, T., Sharrow, S. O., Adams, A., Granger, L., Kruhlak, M., Lindsten, T., Thompson, C. B., et al. (2012) · Blood · doi:10.1182/blood-2011-11-388918 · Cited by 251
B cell regulation of the anti-tumor response and role in carcinogenesis
Schwartz, M., Zhang, Y., & Rosenblatt, J. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0145-x · Cited by 244
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2068 · Cited by 240
Menares, E., Gálvez-Cancino, F., Cáceres-Morgado, P., Ghorani, E., López, E., Díaz, X., Saavedra-Almarza, J., Figueroa, D. A., Roa, E., Quezada, S. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12319-x · Cited by 237
Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
Wang, D., Aguilar, B., Starr, R., Alizadeh, D., Brito, A., Sarkissian, A., Ostberg, J. R., Forman, S. J., & Brown, C. E. (2018) · JCI Insight · doi:10.1172/jci.insight.99048 · Cited by 233
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 232
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Maennling, A. E., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F., Gattenlöhner, S., Meinhold-Heerlein, I., & Hussain, A. F. (2019) · Cancers · doi:10.3390/cancers11121826 · Cited by 218
Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2—A Balancing Act
Kalia, V., & Sarkar, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02987 · Cited by 208
Agarwal, P., Raghavan, A., Nandiwada, S. L., Curtsinger, J. M., Bohjanen, P. R., Mueller, D. L., & Mescher, M. F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900592 · Cited by 203
Gnjatic, S., Atanackovic, D., Jäger, E., Matsuo, M., Selvakumar, A., Altorki, N. K., Maki, R. G., Dupont, B., Ritter, G., Chen, Y.-T., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133324100 · Cited by 203
Ahmadzadeh, M., Pasetto, A., Jia, L., Deniger, D. C., Stevanović, S., Robbins, P. F., & Rosenberg, S. A. (2019) · Science Immunology · doi:10.1126/sciimmunol.aao4310 · Cited by 201
Núñez, N. G., Tosello Boari, J., Ramos, R. N., Richer, W., Cagnard, N., Anderfuhren, C. D., Niborski, L. L., Bigot, J., Meseure, D., De La Rochere, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17046-2 · Cited by 199
Vaccines targeting helper T cells for cancer immunotherapy
Melssen, M., & Slingluff, C. L. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.004 · Cited by 192
In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes
Agarwal, S., Hanauer, J. D. S., Frank, A. M., Riechert, V., Thalheimer, F. B., & Buchholz, C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.005 · Cited by 191
Th9 cells, new players in adaptive immunity
Schmitt, E., Klein, M., & Bopp, T. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.004 · Cited by 189
Lee, H. L., Jang, J. W., Lee, S. W., Yoo, S. H., Kwon, J. H., Nam, S. W., Bae, S. H., Choi, J. Y., Han, N. I., & Yoon, S. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-40078-8 · Cited by 183
STAT6‐dependent and ‐independent mechanisms in Th2 polarization
Maier, E., Duschl, A., & Horejs‐Hoeck, J. (2012) · European Journal of Immunology · doi:10.1002/eji.201242433 · Cited by 181
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Ma, J., Lyu, H., Huang, J., & Liu, B. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-105 · Cited by 180
Dormant tumour cells, their niches and the influence of immunity
Goddard, E. T., Bozic, I., Riddell, S. R., & Ghajar, C. M. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0214-0 · Cited by 178
van de Ven, K., & Borst, J. (2015) · Immunotherapy · doi:10.2217/imt.15.32 · Cited by 177
HER3 signaling and targeted therapy in cancer
Mishra, R., Patel, H., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 174
Anti‐cancer therapy with TNF α and IFN γ: A comprehensive review
Shen, J., Xiao, Z., Zhao, Q., Li, M., Wu, X., Zhang, L., Hu, W., & Cho, C. H. (2018) · Cell Proliferation · doi:10.1111/cpr.12441 · Cited by 170
Lu, Y., Wang, Q., Xue, G., Bi, E., Ma, X., Wang, A., Qian, J., Dong, C., & Yi, Q. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.004 · Cited by 169
CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Davenport, A. J., Jenkins, M. R., Cross, R. S., Yong, C. S. M., Prince, H. M., Ritchie, D. S., Trapani, J. A., Kershaw, M. H., Darcy, P. K., & Neeson, P. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0048 · Cited by 164
Chen, K., & Kolls, J. K. (2017) · Gene · doi:10.1016/j.gene.2017.01.016 · Cited by 164
Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer
Salazar, Y., Zheng, X., Brunn, D., Raifer, H., Picard, F., Zhang, Y., Winter, H., Guenther, S., Weigert, A., Weigmann, B., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci124037 · Cited by 164
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Gall, V., Philips, A. V., Qiao, N., Clise-Dwyer, K., Perakis, A. A., Zhang, M., Clifton, G. T., Sukhumalchandra, P., Ma, Q., Reddy, S. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2774 · Cited by 162
Zhao, Y., Chu, X., Chen, J., Wang, Y., Gao, S., Jiang, Y., Zhu, X., Tan, G., Zhao, W., Yi, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12368 · Cited by 159
Oh, S., Perera, L. P., Terabe, M., Ni, L., Waldmann, T. A., & Berzofsky, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801003105 · Cited by 158
CCL5-Mediated Th2 Immune Polarization Promotes Metastasis in Luminal Breast Cancer
Zhang, Q., Qin, J., Zhong, L., Gong, L., Zhang, B., Zhang, Y., & Gao, W. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3590 · Cited by 156
Prospects of IL-2 in Cancer Immunotherapy
Choudhry, H., Helmi, N. M., Abdulaal, W. H., Zeyadi, M., Zamzami, M. A., Wu, W., Mahmoud, M. M., Warsi, M. K., Rasool, M., & Jamal, M. S. (2018) · BioMed Research International · doi:10.1155/2018/9056173 · Cited by 155
Yang, Z. Z., Grote, D. M., Ziesmer, S. C., Xiu, B., Novak, A. J., & Ansell, S. M. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.1 · Cited by 152
Gray, J. I., Westerhof, L. M., & MacLeod, M. K. L. (2018) · Immunology · doi:10.1111/imm.12929 · Cited by 152
CD4 T Cells Are Required for CD8 T Cell Survival during Both Primary and Memory Recall Responses
Novy, P., Quigley, M. M., Huang, X., & Yang, Y. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.12.8243 · Cited by 151
Lowenfeld, L., Mick, R., Datta, J., Xu, S., Fitzpatrick, E., Fisher, C. S., Fox, K. R., DeMichele, A. M., Zhang, P. J., Weinstein, S. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1924 · Cited by 150
Self-citationMortara, L., Balza, E., Bruno, A., Poggi, A. D., Orecchia, P., & Carnemolla, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02905 · Cited by 144
IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression
Aqbi, H. F., Wallace, M., Sappal, S., Payne, K. K., & Manjili, M. H. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mir0917-351r · Cited by 143
CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities
Ahrends, T., Busselaar, J., Severson, T., Bąbała, N., de Vries, E., Bovens, A. A., Wessels, L. F. A., van Leeuwen, F., & Borst, J. G. (2019) · Nature Communications · doi:10.1038/s41467-019-13438-1 · Cited by 142
Zahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 140
Yasukawa, M., Ohminami, H., Arai, J. A., Kasahara, Y., Ishida, Y., & Fujita, S. (2000) · Blood · doi:10.1182/blood.v95.7.2352 · Cited by 138
Xu, S., Koski, G. K., Faries, M. B., Bedrosian, I., Mick, R., Maeurer, M. J., Cheever, M. A., Cohen, P. A., & Czerniecki, B. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.5.2251 · Cited by 138
Self-citationBeyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity
Noubade, R., Majri-Morrison, S. S., & Tarbell, K. V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01014 · Cited by 136
Nagasaki, J., Togashi, Y., Sugawara, T., Itami, M., Yamauchi, N., Yuda, J., Sugano, M., Ohara, Y., Minami, Y., Nakamae, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002098 · Cited by 135
CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
Ahrends, T., Bąbała, N., Xiao, Y., Yagita∥, H., van Eenennaam, H., & Borst, J. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3130 · Cited by 131
Dendritic Cell-Mediated Th2 Immunity and Immune Disorders
Kumar, S., Ashraf, M. U., Jeong, Y., & Bae, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092159 · Cited by 130
Fu, C., Jiang, L., Hao, S., Liu, Z., Ding, S., Zhang, W., Yang, X., & Li, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02638 · Cited by 129
CD 4+ T‐cell help amplifies innate signals for primary CD 8+ T‐cell immunity
Bedoui, S., Heath, W. R., & Mueller, S. N. (2016) · Immunological Reviews · doi:10.1111/imr.12426 · Cited by 128
Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis
Li, Z., Jiang, J., Wang, Z., Zhang, J., Xiao, M., Wang, C., Yu, L., & Qin, Z. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0449 · Cited by 127
HER2 overexpression correlates with survival after curative resection of pancreatic cancer
Komoto, M., Nakata, B., Amano, R., Yamada, N., Yashiro, M., Ohira, M., Wakasa, K., & Hirakawa, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01176.x · Cited by 126
Scharpenseel, H., Hanssen, A., Loges, S., Mohme, M., Bernreuther, C., Peine, S., Lamszus, K., Goy, Y., Petersen, C., Westphal, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43678-6 · Cited by 124
Determination of T Follicular Helper Cell Fate by Dendritic Cells
Krishnaswamy, J. K., Alsén, S., Yrlid, U., Eisenbarth, S. C., & Williams, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02169 · Cited by 123
Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy
Dobrzanski, M. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00063 · Cited by 122
Dendritic Cells—A Conductor of T Cell Differentiation—
Kadowaki, N. (2007) · Allergology International · doi:10.2332/allergolint.r-07-146 · Cited by 117
Lebre, M. C., Burwell, T., Vieira, P. L., Lora, J., Coyle, A. J., Kapsenberg, M. L., Clausen, B. E., & De Jong, E. C. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01365.x · Cited by 113
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Triulzi, T., Forte, L., Regondi, V., Modica, M. D., Ghirelli, C., Carcangiu, M. L., Sfondrini, L., Balsari, A., & Tagliabue, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512942 · Cited by 110
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Targeting IL4/IL4R for the treatment of epithelial cancer metastasis
Venmar, K. T., & Fingleton, B. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9747-9 · Cited by 108
Nappo, G., Handle, F., Santer, F. R., McNeill, R. V., Seed, R., Collins, A. T., Morrone, G., Čulig, Z., Maitland, N. J., & Erb, H. H. H. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.23 · Cited by 105
Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology
Qin, L., Waseem, T. C., Sahoo, A., Bieerkehazhi, S., Zhou, H. Y., Galkina, E., & Nurieva, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01884 · Cited by 104
Berinstein, N. L., Karkada, M., Oza, A. M., Odunsi, K. O., Villella, J., Nemunaitis, J. J., Morse, M. A., Pejovic, T. B., Bentley, J., Buyse, M. E., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026529 · Cited by 103
Kim, K. H., Kim, H. K., Kim, H., Kim, C. G., Lee, H., Han, J. W., Choi, S. J., Jeong, S., Jeon, M., Kim, H., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0427-6 · Cited by 103
Liadi, I., Singh, H., Romain, G., Rey-Villamizar, N., Merouane, A., Adolacion, J. R. T., Kebriaei, P., Huls, H. M., Qiu, P., Roysam, B., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0195 · Cited by 102
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
Tovey, S., Brown, S., Doughty, J., Mallon, E., Cooke, T. G., & Edwards, J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604940 · Cited by 101
CD40L expression permits CD8+ T cells to execute immunologic helper functions
Frentsch, M., Stark, R., Matzmohr, N., Meier, S., Durlanik, S., Schulz, A. R., Stervbo, U., Jürchott, K., Gebhardt, F., Heine, G., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483586 · Cited by 100 · cited 1×
“Similarity of the cytokine profiles between CD4 T cells and CD8 T cells expressing CD40L has been reported and can potentially augment licensing of DC to enhance ant igen cross-priming (103) .”
BackgroundThe structural network of Interleukin-10 and its implications in inflammation and cancer
Acuner, S. E., Engin, B. H., Guven‐Maiorov, E., Kuzu, G., Muratcioğlu, S., Baspinar, A., Chen, Z., Waes, C. V., Gürsoy, A., Keskin, Ö., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s4-s2 · Cited by 98
Matsushita, H., Sato, Y., Karasaki, T., Nakagawa, T., Kume, H., Ogawa, S., Homma, Y., & Kakimi, K. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0225 · Cited by 98
Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer
Végran, F., Apétoh, L., & Ghiringhelli, F. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2748 · Cited by 96
Park, J. M., Terabe, M., Sakai, Y., Munasinghe, J., Forni, G., Morris, J. C., & Berzofsky, J. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4228 · Cited by 92
Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells.
Hiltbold, E. M., Ciborowski, P. S., & Finn, O. J. (1998) · PubMed · Cited by 90
François, V., Ottaviani, S., Renkvist, N., Stockis, J., Schuler, G., Thielemans, K., Colau, D., Marchand, M., Boon, T., Lucas, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3726 · Cited by 90
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L.-P., Yan, L., Long, M. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0629-6 · Cited by 90
Veatch, J. R., Jesernig, B. L., Kargl, J., Fitzgibbon, M., Lee, S. M., Baik, C., Martins, R., Houghton, A. M., & Riddell, S. R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0402 · Cited by 89
Mego, M., Gao, H., Cohen, E. N., Anfossi, S., Giordano, A., Sanda, T., Fouad, T. M., Giorgi, U. D., Giuliano, M., Woodward, W. A., et al. (2016) · Journal of Cancer · doi:10.7150/jca.13098 · Cited by 88
Takashima, Y., Kawaguchi, A., Kanayama, T., Hayano, A., & Yamanaka, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24897 · Cited by 86
Koski, G. K., Schwartz, G. N., Weng, D. E., Czerniecki, B. J., Carter, C., Gress, R. E., & Cohen, P. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.82 · Cited by 85
Self-citationWelten, S. P. M., Redeker, A., Franken, K. L. M. C., Benedict, C. A., Yagita∥, H., Wensveen, F. M., Borst, J. G., Melief, C. J. M., van Lier, R. A. W., van Gisbergen, K. P. J. M., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03305-12 · Cited by 83
IL-2, IL-7, and IL-15: Multistage regulators of CD4+ T helper cell differentiation
Read, K. A., Powell, M. D., McDonald, P. W., & Oestreich, K. J. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.06.003 · Cited by 83
Th9 Cell Differentiation and Its Dual Effects in Tumor Development
Chen, T., Guo, J., Cai, Z., Li, B., Sun, L., Shen, Y., Wang, S., Wang, Z., Wang, Z., Wang, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01026 · Cited by 83
Hombach, A. A., Köhler, H., Rappl, G., & Abken, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5668 · Cited by 82
Multiple effects of CD40–CD40L axis in immunity against infection and cancer
Ara, A., Ahmed, K. A., & Xiang, J. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s163614 · Cited by 81
Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer.
Wei, L., Niu, Z., Zhang, H., Kong, Y., Wang, Z., Yang, X., & Yuan, F. (2019) · PubMed · Cited by 81
Neoantigens encoded in the cancer genome
Schumacher, T. N., & Hacohen, N. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.07.005 · Cited by 80
TH17 cell plasticity: The role of dendritic cells and molecular mechanisms
Agalioti, T., Villablanca, E. J., Huber, S., & Gagliani, N. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.12.003 · Cited by 80
Transcriptional control of dendritic cell development and functions
Amon, L., Lehmann, C. H. K., Barańska, A., Schoen, J., Heger, L., & Dudziak, D. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.10.001 · Cited by 78
Watanabe, S., Yonesaka, K., Tanizaki, J., Nonagase, Y., Takegawa, N., Haratani, K., Kawakami, H., Hayashi, H., Takeda, M., Tsurutani, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1995 · Cited by 77
Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
Kumai, T., Lee, S., Cho, H.-I., Sultan, H., Kobayashi, H., Harabuchi, Y., & Celis, E. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0194 · Cited by 75
Faries, M. B., Bedrosian, I., Xu, S., Koski, G. K., Roros, J. G., Moise, M. A., Nguyen, H. Q., Engels, F. H. C., Cohen, P. A., & Czerniecki, B. J. (2001) · Blood · doi:10.1182/blood.v98.8.2489 · Cited by 74
Self-citationHong, C., Yao, S., McCann, S. E., Dolnick, R. Y., Wallace, P. K., Gong, Z., Quan, L., Lee, K. P., Evans, S. S., Repasky, E. A., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2549-3 · Cited by 72
Datta, J., Fracol, M. E., McMillan, M. T., Berk, E., Xu, S., Goodman, N. G., Lewis, D. A., DeMichele, A. M., & Czerniecki, B. J. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5482 · Cited by 71
Self-citationDatta, J., Rosemblit, C., Berk, E., Showalter, L., Namjoshi, P., Mick, R., Lee, K. P., Brod, A. M., Yang, R. L., Kelz, R. R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1022301 · Cited by 66
Self-citationCD4 + T help promotes influenza virus-specific CD8 + T cell memory by limiting metabolic dysfunction
Cullen, J. G., McQuilten, H. A., Quinn, K. M., Olshansky, M., Russ, B. E., Morey, A., Wei, S., Prier, J. E., Gruta, N. L. L., Doherty, P. C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808849116 · Cited by 66
Bae, S. Y., Choi, Y., Kim, S., Kim, M., Kim, J., Jung, S. P., Choi, M.-Y., Lee, S. K., Kil, W. H., Lee, J. E., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2570-6 · Cited by 61
Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy
Terhune, J. H., Berk, E., & Czerniecki, B. J. (2013) · Vaccines · doi:10.3390/vaccines1040527 · Cited by 60
Self-citationJia, Y., Kodumudi, K. N., Ramamoorthi, G., Basu, A. B., Snyder, C., Wiener, D. A., Pilon‐Thomas, S., Grover, P., Zhang, H., Greene, M. I., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.037 · Cited by 60
Self-citationArbelaez, C. A., Estrada, J., Gessner, M. A., Glaus, C., Morales, A. B., Mohn, D., Phee, H., Lipford, J. R., & Johnston, J. A. (2020) · npj Vaccines · doi:10.1038/s41541-020-00253-9 · Cited by 59
Ogden, A., Bhattarai, S., Sahoo, B., Mongan, N. P., Alsaleem, M. A., Green, A. R., Aleskandarany, M. A., Ellis, I. O., Pattni, S., Li, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59514-1 · Cited by 58
Dendritic cell vaccines for high-grade gliomas
Eagles, M. E., Nassiri, F., Badhiwala, J. H., Suppiah, S., Almenawer, S. A., Zadeh, G. M., & Aldape, K. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s135865 · Cited by 57
Bretscher, P. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01234 · Cited by 57
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Harnessing innate immune pathways for therapeutic advancement in cancer
Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 255
Moreno Ayala, M. A., Campbell, T. F., Zhang, C., Dahan, N., Bockman, A., Prakash, V., Feng, L., Sher, T., & DuPage, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.003 · Cited by 241
Mhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009517 · Cited by 43
Metadata
- Authors
- Basu, A., Ramamoorthi, G., Albert, G., Gallen, C., Beyer, A., Snyder, C., Koski, G., Disis, M. L., Czerniecki, B. J., & Kodumudi, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-05-03
- Volume
- 12
- Pages
- 669474-669474
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3158086066
- Cited by
- 321
- References
- 229
- FWCI
- 16.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.